- Country: Argentina
- Summary: Medicines-pcte: Ifran Maxima-pharmacia
- ART Ref No: 100254813
- Deadline: 23 Apr 2024
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: ARS 1333800.00
- Notice Type: Tender
- Document Ref. No.: 430-0697-CDI24
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Diclofenac + Vitamin B12 + Betamethasone. Model: 75 mg of potassium diclofenac + 2.63 mg of betamethasone phosphate + 10 mg of vitamin B12, injectable, lyophilized, in a blistering bottle + Ampolla Solve see more, vitamin D3. Model: 1 µg, in capsule, carboxymethyl sodium cellulose. Model: at 0.5 %, Colirio, in Gotero X 10 ml bottle, Valsartan. Model: 80 mg, in capsule, vitamin enrichment supplement Model: containing mixture of lyiophilized growth factors, expiration not less than one year variety: vitamin enrichment, complete liquid nutrition approximate composition per 100cc. Proteins (ca, Na and Mg case Fats: 9.3 to 9.6g. see more
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINMedicines-pcte: Ifran Maxima-pharmacia - Argentina Tender
The HTAL. JOSE M. WE MEJIA, a Government sector organization in Argentina, has announced a new tender for Medicines-pcte: Ifran Maxima-pharmacia. This tender is published on ArgentinaTenders under ART Ref No: 100254813 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2024-04-23.
The estimated tender value is ARS 1333800.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
